Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap Up to $133.66

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares gapped up prior to trading on Tuesday . The stock had previously closed at $133.66, but opened at $141.00. Neurocrine Biosciences shares last traded at $141.02, with a volume of 432,096 shares traded.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on NBIX shares. Citigroup dropped their price target on Neurocrine Biosciences from $141.00 to $140.00 and set a “neutral” rating for the company in a research report on Thursday, February 8th. Wells Fargo & Company lifted their target price on shares of Neurocrine Biosciences from $127.00 to $140.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 8th. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a research report on Tuesday. The Goldman Sachs Group lifted their price objective on Neurocrine Biosciences from $134.00 to $153.00 and gave the stock a “buy” rating in a research report on Thursday, January 25th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a report on Wednesday, April 10th. Seven equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $139.67.

Neurocrine Biosciences Stock Up 4.7 %

The firm has a market capitalization of $13.93 billion, a price-to-earnings ratio of 55.23 and a beta of 0.25. The company has a 50-day moving average price of $136.21 and a 200-day moving average price of $127.35.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.31. The company had revenue of $515.20 million for the quarter, compared to the consensus estimate of $518.52 million. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The company’s quarterly revenue was up 25.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.88 EPS. As a group, analysts forecast that Neurocrine Biosciences, Inc. will post 4.84 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Richard F. Pops sold 15,000 shares of the stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $132.47, for a total value of $1,987,050.00. Following the completion of the transaction, the director now owns 29,512 shares in the company, valued at approximately $3,909,454.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Richard F. Pops sold 1,700 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $140.05, for a total transaction of $238,085.00. Following the completion of the sale, the director now directly owns 29,512 shares in the company, valued at $4,133,155.60. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Richard F. Pops sold 15,000 shares of Neurocrine Biosciences stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $132.47, for a total transaction of $1,987,050.00. Following the sale, the director now directly owns 29,512 shares of the company’s stock, valued at approximately $3,909,454.64. The disclosure for this sale can be found here. Insiders have sold 186,994 shares of company stock worth $25,806,409 in the last three months. 4.60% of the stock is currently owned by insiders.

Institutional Trading of Neurocrine Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the company. Mather Group LLC. purchased a new position in Neurocrine Biosciences in the first quarter valued at about $26,000. Headinvest LLC acquired a new stake in shares of Neurocrine Biosciences during the 3rd quarter valued at about $28,000. Lindbrook Capital LLC grew its stake in shares of Neurocrine Biosciences by 85.0% in the 4th quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock valued at $28,000 after buying an additional 96 shares in the last quarter. EdgeRock Capital LLC bought a new stake in shares of Neurocrine Biosciences in the 4th quarter valued at approximately $31,000. Finally, Benjamin F. Edwards & Company Inc. acquired a new position in Neurocrine Biosciences in the fourth quarter worth approximately $33,000. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.